HMNC Brain Health aims to accelerate the market readiness of its therapy with the newly raised funds. The Munich-based BiotechThe startup is working on a personalized therapy approach for the treatment of depression and treatment-resistant depression. The goal of this approach is to shorten treatment duration, improve treatment outcomes, and reduce the risk of relapse. The funding will enable HMNC Brain Health to focus on two CRO-led (Editor's note: Contract research institute-led) To prepare proof-of-concept studies, drive strategic growth initiatives and strengthen the HMNC team.
“The continued support of our existing shareholders demonstrates their confidence in the Company’s strategic direction and our potential to develop a unique pipeline in Precision Psychiatry,”
so Benedict of Braunmühl, CEO of HMNC Brain Health.
Driving forward the strategic agenda
"These funds will enable HMNC to advance our strategic agenda, taking another step toward improving the quality of life for patients around the world suffering from depression or other neuropsychiatric disorders."
And Carsten Maschmeyer, co-founder and supervisory board member of the Munich-based startup, added:
"We are excited by the progress of the clinical pipeline. We are confident in HMNC and will accompany and support it wherever we can on its journey to becoming a leader in precision psychiatry."
